Desloratadine

證據等級: L5

預測適應症: 10 個

Desloratadine: From Allergic Rhinitis to Cold Urticaria

One-Sentence Summary

Desloratadine is a second-generation, non-sedating H1-antihistamine widely used globally for allergic rhinitis and chronic urticaria, though currently unregistered in Taiwan. The TxGNN model predicts it may be effective for Cold Urticaria (acquired cold urticaria), with 3 clinical trials and 7 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Allergic rhinitis and chronic idiopathic urticaria (based on international approvals; no Taiwan license on record)
Predicted New Indication	Cold Urticaria
TxGNN Prediction Score	99.94%
Evidence Level	L1
Taiwan Market Status	Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, desloratadine is a selective peripheral H1-receptor antagonist and the active metabolite of loratadine. As a second-generation antihistamine, it is non-sedating, has a prolonged duration of action, and carries anti-inflammatory properties beyond pure receptor blockade — including suppression of mast cell degranulation and downregulation of pro-inflammatory adhesion molecules (ICAM-1, VCAM-1).

Acquired cold urticaria (ACU) is a physical urticaria triggered by cold stimuli. The cold challenge induces mast cell degranulation and histamine release, producing wheals, flare, and — in severe cases — anaphylaxis. Desloratadine addresses this at two levels: it competitively blocks H1 receptors to reduce downstream wheal formation, and it inhibits the upstream IgE-dependent mast cell activation pathway, thereby raising the critical temperature threshold (CTT) — the minimum cold exposure required to provoke a reaction.

This mechanistic fit is direct and well-supported: histamine is the principal mediator of ACU, and H1-receptor antagonism is the first-line treatment recommended by EAACI/GA²LEN/EDF urticaria guidelines. High-dose desloratadine (20 mg) has been shown to be significantly more effective than the standard 5 mg dose in reducing wheal volume and improving CTT, making cold urticaria one of the most biologically coherent applications in the TxGNN prediction set.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01444196	Phase 4	Completed	30	Multi-center, double-blind, dose-escalation study comparing 5 mg, 10 mg, and 20 mg desloratadine; primary aim was to identify the dose sufficient to inhibit ACU symptoms
NCT00600847	Phase 4	Completed	33	Randomized, double-blind, placebo-controlled crossover study; compared cold urticaria lesion size (thermography, volumetry) under placebo vs. 5 mg vs. 20 mg desloratadine; tested hypothesis that updosing is more effective than standard dose
NCT01940393	Phase 4	Completed	150	Head-to-head comparison of 5 antihistamines (including desloratadine) in urticaria patients in tropical Latin America; largest enrollment in the set, provides comparative efficacy and pharmacodynamic data

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22242678	2012	RCT	British Journal of Dermatology	Dose escalation of H1-antihistamines in cold urticaria; used critical temperature threshold as primary endpoint; demonstrated measurable improvement with higher dosing
19201016	2009	Controlled Trial	J Allergy and Clinical Immunology	High-dose desloratadine (20 mg) significantly decreased wheal volume and improved cold provocation thresholds vs. standard dose and placebo; randomized, placebo-controlled, crossover design; supports guideline recommendation for updosing
14754651	2004	Controlled Clinical Study	J Dermatological Treatment	Desloratadine 5 mg for 4 days significantly inhibited cold urticaria in 12 patients using ice-cube challenge before and after treatment; early controlled evidence of direct efficacy
15516152	2004	Review	Drugs	Comprehensive review of chronic urticaria aetiology and management; positions H1-antihistamines, including desloratadine, as first-line standard of care
19032340	2008	Review	Allergy	Comparative review of second-generation antihistamines in allergic rhinitis and chronic urticaria; includes head-to-head comparisons with desloratadine
29698807	2018	Case Series	J Allergy Clin Immunol In Practice	Food-dependent cold urticaria described as a new physical urticaria variant; characterizes clinical features and management approaches relevant to this indication
38025339	2023	Case Report	Qatar Medical Journal	First reported case of cold-induced urticaria following black ant bite anaphylaxis; illustrates mechanistic diversity within the cold urticaria spectrum

Taiwan Market Information

Desloratadine currently has no marketing authorizations in Taiwan. No licensed products, approved indications, or registered dosage forms are on record with the TFDA.

Safety Considerations

Please refer to the SmPC for safety information. Full TFDA label warnings and contraindications were not available in this Evidence Pack (Data Gap DG001: TFDA 仿單警語/禁忌, severity: Blocking).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Three completed Phase 4 clinical trials — including a randomized, double-blind, placebo-controlled crossover study — directly evaluating desloratadine in acquired cold urticaria, combined with an independent RCT (PMID 22242678) and six additional supporting publications, constitute L1-level evidence. The mechanistic fit is unambiguous: histamine is the primary mediator of ACU, H1-receptor antagonism is the guideline-recommended first-line treatment, and dose-escalation to 20 mg has demonstrated quantifiably superior efficacy over standard dosing.

To proceed, the following is needed:

TFDA label (仿單) for Taiwan-specific safety warnings and contraindications (DG001 — Blocking; download from TFDA official website)
Complete mechanism of action data from DrugBank API (DG002 — High)
Taiwan registration pathway assessment — desloratadine is currently unregistered; a regulatory strategy (new drug application, or identification of an existing imported brand) is required before clinical use
Pharmacogenomic review for Taiwanese patient population, particularly CYP3A4/CYP2D6 metabolism considerations relevant to dose-escalation safety
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.